184 related articles for article (PubMed ID: 35780655)
1. Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
Pu C; Wang S; Luo D; Liu Y; Ma X; Zhang H; Yu S; Lan S; Huang Q; Deng R; He X; Li R
Bioorg Med Chem; 2022 Sep; 69():116908. PubMed ID: 35780655
[TBL] [Abstract][Full Text] [Related]
2. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
[TBL] [Abstract][Full Text] [Related]
3. Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
Pu C; Tong Y; Liu Y; Lan S; Wang S; Yan G; Zhang H; Luo D; Ma X; Yu S; Huang Q; Deng R; Li R
Eur J Med Chem; 2022 Jun; 236():114321. PubMed ID: 35430559
[TBL] [Abstract][Full Text] [Related]
4. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer.
Wu Y; Wu M; Zheng X; Yu H; Mao X; Jin Y; Wang Y; Pang A; Zhang J; Zeng S; Xu T; Chen Y; Zhang B; Lin N; Dai H; Wang Y; Yao X; Dong X; Huang W; Che J
Bioorg Chem; 2024 Jan; 142():106952. PubMed ID: 37952486
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
9. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
[TBL] [Abstract][Full Text] [Related]
10. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
11. Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
Cao C; Yang J; Chen Y; Zhou P; Wang Y; Du W; Zhao L; Chen Y
J Med Chem; 2020 Oct; 63(19):11012-11033. PubMed ID: 32924477
[TBL] [Abstract][Full Text] [Related]
12. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
[TBL] [Abstract][Full Text] [Related]
13. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
14. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule.
Zhao Q; Lan T; Su S; Rao Y
Chem Commun (Camb); 2019 Jan; 55(3):369-372. PubMed ID: 30540295
[TBL] [Abstract][Full Text] [Related]
17. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
Zheng M; Huo J; Gu X; Wang Y; Wu C; Zhang Q; Wang W; Liu Y; Liu Y; Zhou X; Chen L; Zhou Y; Li H
J Med Chem; 2021 Jun; 64(11):7839-7852. PubMed ID: 34038131
[TBL] [Abstract][Full Text] [Related]
18. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.
Lin S; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Wu L
Bioorg Med Chem; 2022 May; 61():116739. PubMed ID: 35393219
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
